These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates. Leonard JE; Wang QC; Kaplan NO; Royston I Cancer Res; 1985 Nov; 45(11 Pt 1):5263-9. PubMed ID: 3876881 [TBL] [Abstract][Full Text] [Related]
4. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity. Pietersz GA; Kanellos J; McKenzie IF Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814 [TBL] [Abstract][Full Text] [Related]
5. [Cancer and the lymphatic system]. Grekh IF Vopr Onkol; 1971 Sep; 17(10):101-10. PubMed ID: 4947716 [No Abstract] [Full Text] [Related]
6. The potential use of immunotoxins in transplantation, cancer therapy, and immunoregulation. Vitetta ES; Uhr JW Transplantation; 1984 Jun; 37(6):535-8. PubMed ID: 6375011 [No Abstract] [Full Text] [Related]
7. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599 [TBL] [Abstract][Full Text] [Related]
8. [Increasing the immune status of the body during the tumor process by using several biologically active substances]. Veksler IG Fiziol Zh; 1977; 23(6):758-63. PubMed ID: 590553 [No Abstract] [Full Text] [Related]
9. Activated macrophages and the antitumor action of BCG. Alexander P Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313 [No Abstract] [Full Text] [Related]
11. [Use of monoclonal antibodies in the immunotherapy of neoplasms]. Robak T Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121 [No Abstract] [Full Text] [Related]
12. [Antitumor immunoadjuvant activity and the immunoregulatory mechanisms of yeasts and their components]. Marconi P; Bistoni F Ann Ist Super Sanita; 1982; 18(3):501-8. PubMed ID: 6765083 [No Abstract] [Full Text] [Related]
13. Immunity to malignant disease in man. Fairley GH Sci Basis Med Annu Rev; 1971; ():17-38. PubMed ID: 4933915 [No Abstract] [Full Text] [Related]
14. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. Colombatti M; Johnson VG; Skopicki HA; Fendley B; Lewis MS; Youle RJ J Immunol; 1987 May; 138(10):3339-44. PubMed ID: 2437188 [TBL] [Abstract][Full Text] [Related]
15. Changes in the opsonin and cellular influences on phagocytosis during the growth of transplantable tumors. Kampschmidt RF; Pulliam LA J Reticuloendothel Soc; 1972 Jan; 11(1):1-10. PubMed ID: 5060134 [No Abstract] [Full Text] [Related]
16. Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli. Weiss DW Natl Cancer Inst Monogr; 1972 Dec; 35():157-71. PubMed ID: 4633406 [No Abstract] [Full Text] [Related]
17. [New developments in the treatment of cancer]. Salamanca-Gómez F Gac Med Mex; 1999; 135(6):659-61. PubMed ID: 10605270 [No Abstract] [Full Text] [Related]
18. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Schmidberger H; King L; Lasky LC; Vallera DA Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Bjorn MJ; Ring D; Frankel A Cancer Res; 1985 Mar; 45(3):1214-21. PubMed ID: 3971370 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Weil-Hillman G; Runge W; Jansen FK; Vallera DA Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]